Literature DB >> 29309776

Glycome Patterns of Perfusate in Livers Before Transplantation Associate With Primary Nonfunction.

Xavier Verhelst1, Anja Geerts1, Ina Jochmans2, Dieter Vanderschaeghe3, Agnes Paradissis1, Aude Vanlander4, Frederik Berrevoet4, Géraldine Dahlqvist5, Frederik Nevens6, Jacques Pirenne2, Xavier Rogiers4, Nico Callewaert3, Roberto I Troisi4, Hans Van Vlierberghe7.   

Abstract

BACKGROUND & AIMS: Primary nonfunction (PNF) is a rare complication after liver transplantation that requires urgent retransplantation. PNF is associated with livers from extended criteria donors. Clinical and biochemical factors have not been identified that reliably associate with graft function after liver transplantation. Serum patterns of N-glycans associate with changes in the liver. We analyzed perfusate from grafted liver to identify protein glycosylation patterns associated with PNF.
METHODS: We performed a prospective study of consecutive patients who underwent liver transplantation (66 patients, from 1 center, in the derivation set, and 56 patients, from 2 centers, in the validation set) in Belgium, from October 1, 2011, through April 30, 2017. All donor grafts were transported using cold static storage, and perfusate samples were collected from the livers by flushing of hepatic veins before transplantation. Protein-linked N-glycans were isolated from perfusate samples and analyzed with a multicapillary electrophoresis-based ABI3130 sequencer. We compared glycan patterns between patients with vs without PNF of transplanted livers. PNF was defined as the need for urgent retransplantation when a graft had no evidence of function, after exclusion of other causes, such as hepatic artery thrombosis or acute cellular rejection.
RESULTS: The relative abundance of a single glycan, agalacto core-alpha-1,6-fucosylated biantennary glycan (NGA2F) was significantly increased in perfusate of livers given to 4 patients who developed PNF after liver transplantation compared with livers given to patients who did not develop PNF. Level of NGA2F identified patients with PNF with 100% accuracy. This glycomarker was the only factor associated with PNF in multivariate analysis in the derivation and the validation sets (P < .0001).
CONCLUSIONS: In an analysis of patients who underwent liver transplantation, we associated graft perfusate level of glycan NGA2F present on perfusate proteins with development of PNF with 100% accuracy, and validated this finding in a separate cohort of patients. This biomarker might be used to assess grafts before transplantation, especially when high-risk organs are under consideration.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glycan; Glycomics; Hepatocyte; Liver Failure; Primary Nonfunction; Secretion

Mesh:

Substances:

Year:  2018        PMID: 29309776     DOI: 10.1053/j.gastro.2017.12.027

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  4 in total

Review 1.  Set Up for Failure: Pre-Existing Autoantibodies in Lung Transplant.

Authors:  Alexander McQuiston; Amir Emtiazjoo; Peggi Angel; Tiago Machuca; Jason Christie; Carl Atkinson
Journal:  Front Immunol       Date:  2021-08-11       Impact factor: 7.561

Review 2.  Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools-a narrative review.

Authors:  Natalia Rosso; Adam M Stephenson; Pablo J Giraudi; Claudio Tiribelli
Journal:  Ann Transl Med       Date:  2021-04

Review 3.  Impact of Machine Perfusion on Biliary Complications after Liver Transplantation.

Authors:  Andrea Schlegel; Philipp Dutkowski
Journal:  Int J Mol Sci       Date:  2018-11-12       Impact factor: 5.923

4.  Primary nonfunction following liver transplantation: Learning of graft metabolites and building a predictive model.

Authors:  Xueyou Zhang; Cheng Zhang; Haitao Huang; Ruihan Chen; Yimou Lin; Leiming Chen; Lili Shao; Jimin Liu; Qi Ling
Journal:  Clin Transl Med       Date:  2021-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.